From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Presidential highlights
This year’s ESMO marked a significant milestone in bladder cancer research. Prof Thomas Powles from Barts Cancer Centre in London, UK, unveiled revolutionary data that is poised to significantly alter
MediMix is honored to bring an exclusive interview with Dr. Oliver Sartor, a renowned medical oncologist from Mayo Clinic, Rochester, MN. He had the privilege of discussing the PSMAfore trial
This year’s ESMO congress was a landmark event for research in urothelial carcinoma. The introduction of two studies that demonstrated effective treatment alternatives to chemotherapy, the standard of care for
Daily highlights in GU
Dr Annelies Verbiest, a medical oncologist at the University Hospital of Antwerp, has presented noteworthy findings from the mini-oral sessions on non-prostate genitourinary tumours.
Two trials investigated an intravesical drug
Marco Gizzi, medical oncologist working at the Grand Hôpital de Charleroi and in Clinique Universitaires Saint-Luc, Brussels, had the privilege to present the highlights on prostate cancer during the ESMO
Dr. Pierre Frères, a medical oncologist at CHU de Liège, provided an overview of the genitourinary tumors session at ESMO2023.
In the Phase 3 THOR-2 study, erdafitinib was compared to pembrolizumab
Dr. Emmanuel Seront, medical oncologist at Clinique Universitaire Saint-Luc, discussed the findings presented in the proffered paper session on renal cancer.
The randomized open-label Phase 3 LITESPARK-005 study compared the
In-depth stories about GU
In a discussion led by Prof Christof Vulsteke, a medical oncologist at the Integrated Cancer Center and Maria Middelares in Ghent, and Dr Michiel Strijbos, a medical oncologist at GZA
Dr Michiel Strijbos, a GU oncologist at GZA Wilrijk, and prof. Christian Gratzke, a urologist from Freiburg, Germany, engaged in a discussion on the potential of immunotherapy in the context
Dr Michiel Strijbos, a GU oncologist at GZA Wilrijk, conducts an insightful interview with Prof Henrik Grönberg from the Karolinska Institute in Stockholm, shedding light on the innovative ProBio trial,
Dr. Michiel Strijbos, a medical oncologist at GZA Wilrijk, and Dr. Peter Schatteman, a urologist at OLV Aalst, discussed key aspects of the LITESPARK trials presented at the ESMO meeting.
Prof Bertrand Tombal, an oncologic urologist from Clinique Universitaires Saint-Luc in Brussels, delivered a presentation on metastatic hormone-naïve prostate cancer during a specialized session. This area of study has seen
Dr Emmanuel Seront, medical oncologist at Clinique Universitaires Saint-Luc and Dr Marco Gizzi medical oncologist working at the Grand Hôpital de Charleroi and in Clinique Universitaires Saint-Luc, engaged in a
GU poster selection
Immune-checkpoint blockade (ICB) can achieve durable benefit in advanced renal cell carcinoma (aRCC), but reliable biomarkers are lacking. Lisa Kinget, medical oncology resident at UZ Leuven, summarized her PhD research
With the educational support of: